A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer

Investigational New Drugs

Volumn 33, Issue 4, 2015, Pages 890-894

  Mitri, Zahi ^a   Karakas, Cansu ^b   Wei, Caimiao ^a   Briones, Brian ^a   Simmons, Holly ^a   Ibrahim, Nuhad ^a   Alvarez, Ricardo ^a   Murray, James L ^a   Keyomarsi, Khandan ^b   Moulder, Stacy ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE   (United States)

Author keywords

Dinaciclib; Epirubicin; Metastatic; Phase 1 study; Systemic treatment; Triple negative breast cancer

Indexed keywords

DINACICLIB; EPIRUBICIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLIN DEPENDENT KINASE; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE INHIBITOR; PYRIDINIUM DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BACKACHE; BREAST METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPERKALEMIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NIGHT SWEAT; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; TRIPLE NEGATIVE BREAST CANCER; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLIN-DEPENDENT KINASES; EPIRUBICIN; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINIUM COMPOUNDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84944160120     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-015-0244-4     Document Type: Article

References (18)

1. Lobbezoo DJ et al (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141(3):507-14
2. Weide R et al (2014) Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors. Springerplus 3:535
3. Keyomarsi K et al (2002) Cyclin E and survival in patients with breast cancer. N Engl J Med 347(20):1566-75
4. Wingate H et al (2005) The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280(15):15148-57
5. Porter DC et al (2001) Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21(18):6254-69
6. Corin I et al (2006) Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in nonmetastatic colorectal tumors. Cancer Biol Ther 5(2):198-203
7. Bedrosian I et al (2004) Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene 23(15):2648-57
8. Akli S et al (2004) Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64(9):3198-208
9. Akli S et al (2007) Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67(15):7212-22
10. Nanos-Webb A et al (2012) Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat 132(2):575-88
11. Nemunaitis JJ et al (2013) A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 11:259
12. Ortiz-Ferron G et al (2008) Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 18(6):664-76
13. Paruch K et al (2010) Discovery of dinaciclib (SCH 727965): a potent and selective inhibitor of cyclin-dependent kinases. ACS Med Chem Lett 1(5):204-8
14. Parry D et al (2010) Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 9(8):2344-53
15. Mita MM et al (2014) Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer. Clin Breast Cancer 14(3):169-76
16. Ji Y, Li Y, Nebiyou Bekele B (2007) Dose-finding in phase I clinical trials based on toxicity probability intervals. Clin Trials 4(3):235-44
17. Mita, M.M., et al. (2011) A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. J Clin Oncol 29(15)
18. Fabre C et al (2014) Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemother Pharmacol 74(5):1057-64